New research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing promising outcomes in treating obesity and diabetes 2 condition. Animal evidence suggest a novel action contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/